SepTec, elected as the most innovative Start-up in Europe
Among 80 applications, 30 start-ups were selected to pitch during the Start-up Slams at MedFIT in different categories such as cardiovascular, AI/Big data, cancer, generic tools, diagnostic, monitoring and coating / implants / wound. SepTec, an Irish start-up represented by Dr. Elaine Spain, co-founder and co-inventor, is the winner of this year’s edition of the Start-up Slams, from the diagnostic category.
“SepTec was honored to be accepted to pitch at MedFIT 2019 in the Start-up Slams as well as being awarded a stand to showcase our technology. This not only gave us the opportunity to highlight the benefits of SepTec but to interact with international key opinion leaders and experts in MedTech and diagnostics. Winning the “most innovative start-up” award has already significantly enhanced SepTec’s visibility in all of these sectors.” Dr. Elaine Spain – Co-founder and co-inventor
SepTec is developing a sample-to-answer IVD test that can rapidly detect sepsis causing pathogens in whole blood within 15 minutes. SepTec is composed of highly accomplished, aspiring entrepreneurial scientists, engineers and clinical key opinion leaders with a clear focus to address unmet clinical needs, such as empowering an ICU Consultant to rapidly detect infection in a seriously ill patient. In collaboration with Science foundation Ireland, Enterprise Ireland, Dublin City University, Business Experts and International Manufacturers, SepTec has created a powerful microfluidic device that can address the specific unmet clinical needs as expressed by their network of clinicians. SepTec is currently completing clinical device validation using suspected sepsis patient samples in collaboration with two Dublin based hospital locations and is determinedly working to accelerate the SepTec device to the next stage of commercialisation.
Mikro Biyosistemler, elected as the most promising technology in Europe
35 TTOs, universities, research institutes and companies applied to the Collaborative and Licensing Opportunity Presentations to showcase their technology in front of potential partners in order to entail a collaborative project and / or a licensing deal. 11 of them have been selected to pitch during MedFIT in 4 different categories: cardiovascular/nutrition, imaging, injection/needle and diagnostic. Mikro Biyosistemler, founded in 2015 and represented by Özge Zorlu, CTO, received the “Most promising Technology” award.
“We applied for a presentation at the Collaborative and Licensing Opportunities Presentations to introduce our new technology to our potential collaborators and investors. I was honored that we were granted with this prize among many brilliant ideas and presentations. We are very happy that we will be at MedFIT2020 as a result of this award. This will be the 3rd time in a row, and we already feel as a part of MedFIT.” Özge Zorlu, PhD – CTO
Mikro Biyosistemler is a university spin-off developing biomedical microsystems. Their core product is a liquid biopsy platform which uses a simple blood sample for cancer diagnostics and cancer research. The patent-pending microfluidic technology enables isolation and enumeration of Circulating Tumor Cells from the blood samples of cancer patients. Mikro Biyosistemler plans to launch their first products in late 2020. Mikro Biyosistemler recently started working on a new product which is a rapid point-of-care diagnostic finger prick blood test which gives White Blood Cell differential count to assess whether the infection is bacterial or viral, aimed to reduce unnecessary prescription of antibiotics. Mikro Biyosistemler is in collaboration with several Turkish and other European hospitals and companies for the validation of their products.
